Why did reported earnings decline in 1994 if the core business grew?

Reported net earnings fell to $1.84 billion from $1.96 billion because of a $750 million pre-tax special charge in Q4 1994 for pending and future breast implant product liability claims. Pre-tax earnings before this charge rose 8% to $3.31 billion, and net earnings before the charge rose 3% to $2.33 billion. The 1993 results also included a $500 million charge, so the comparison is affected by both years.

How large could the breast implant liability ultimately be?

The settlement caps the aggregate contribution of the Company and its subsidiary MEC at $1.154 billion, paid over roughly 30 years. The company recorded $1.5 billion of liabilities in 1993 against $1 billion of expected insurance proceeds, and then took the additional $750 million charge in 1994. However, about 3,000 U.S. opt-outs and about 2,200 foreign opt-outs may bring claims outside the settlement, and the company says the cost of resolving them cannot be reliably estimated. Further charges are possible, and the timing of a potential trigger for settlement reductions is uncertain, though likely not before late 1995.

What is the biggest patent risk for the company's largest product?

Captopril, sold mainly as CAPOTEN, is the company's largest-selling product, with 1994 sales of $1.5 billion, of which $581 million were in the U.S. Under legislation implementing the GATT treaty, the U.S. patent expiration was pushed to February 1996. The company says the financial effect of this new date is still being evaluated because of open questions about how the GATT legislation will be implemented. In Germany, patent protection for CAPOTEN expired in February 1995.

Is the company's balance sheet strong enough to support its dividend and investments?

Yes, based on the filing. At year-end 1994 the company held $2.4 billion in cash, time deposits and marketable securities. Operating cash flow was $2.3 billion, which funded about $1.5 billion in dividends, $573 million in capital expenditures, and $667 million for acquisitions. The company also has a triple-A credit rating and substantial unused borrowing capacity. However, short-term borrowings rose to $725 million, largely to finance the UPSA acquisition, and working capital fell from prior years.

What drove growth in the pharmaceutical business?

Pharmaceutical sales grew 7% to $6.97 billion, mainly from volume, with price increases adding about 1%. Cardiovascular drugs reached $2.8 billion and grew 8%, helped by Pravachol and Monopril. Anti-cancer sales rose 13% to $1.3 billion, with Taxol performing strongly after its April 1994 U.S. clearance for metastatic breast cancer. CNS drugs grew 17%, led by Stadol NS and Buspar. Anti-infective sales declined 2% to $1.5 billion, as generic competition for Amikin and lower sales of Azactam and Videx offset gains in Cefzil and Zerit. The company also received FDA approval for Serzone in December 1994 and expects to launch Glucophage in 1995.

BMY 10-K FY1994 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 29, 1995. Cited figures are marked; the original filing is the authoritative source.

Bristol-Myers Squibb's 1994 10-K shows a company whose core earnings power remained strong but whose reported results were dominated by a large, escalating breast implant litigation charge.

Net sales rose 5% to $11.98 billion^a, with volume growth as the main driver and pricing contributing about 1%. Excluding special product liability charges, pre-tax earnings grew 8% to $3.31 billion and EPS rose 4% to $4.58. Reported net earnings fell about 6% to $1.84 billion, or $3.62 per share, because of a $750 million pre-tax special charge in Q4 1994 tied to breast implant claimant opt-outs, following a $500 million charge in 1993.

The pharmaceutical segment, at 58% of sales, was the growth engine, rising 7% to $6.97 billion^b. Key drivers were cardiovascular drugs (led by captopril and Pravachol), the anti-cancer franchise (up 13%, with Taxol strong), and the central nervous system line (up 17%). Management highlighted recent acquisitions, including the remaining stake in the UPSA analgesics group, Matrix Essentials in hair care, and Calgon Vestal.

It also flagged near-term patent risk: the U.S. captopril patent expiration was extended by GATT legislation to February 1996, and its effect is still being evaluated. R&D spending held at $1.1 billion^c, about 13.6% of pharmaceutical sales. The balance sheet remains conservative.

The company held $2.4 billion^d in cash, time deposits and marketable securities, carried a triple-A credit rating, and generated $2.3 billion in operating cash flow, which funded roughly $1.5 billion in dividends. The dividend was raised to a 1995 indicated annual rate of $2.96.

The main open risk is the breast implant matter: about 20,000 plaintiffs have sued, roughly 3,000 U.S. opt-outs may assert claims, the company's total settlement contribution is capped at $1.154 billion over about 30 years, and further charges cannot be ruled out, with a trigger point possibly arriving in late 1995. Coverage litigation against insurers is also pending.

02—Key points

Key Highlights

Net sales rose 5% to $11.98 billion in 1994, driven mainly by volume; domestic sales grew 4% and international sales grew 7%.
Reported EPS fell to $3.62 from $3.80 because of a $750 million pre-tax breast implant special charge; excluding special charges, EPS rose 4% to $4.58.
The pharmaceutical segment (58% of sales) grew 7% to $6.97 billion, led by cardiovascular drugs ($2.8 billion), anti-cancer drugs (+13%), and CNS drugs (+17%).
Patent risk: the U.S. captopril (CAPOTEN) patent expiration was extended by GATT legislation to February 1996, and its impact on overall performance is still being evaluated.
Strong liquidity: $2.4 billion in cash and marketable securities, triple-A credit rating, and $2.3 billion in operating cash flow covering roughly $1.5 billion in dividends.
Dividend raised: the 1995 indicated annual payment is $2.96 per common share, up from $2.92 in 1994, with a 13% compound annual growth rate over ten years.
Breast implant litigation remains the key uncertainty: about 20,000 plaintiffs, a settlement capped at $1.154 billion over 30 years, roughly 3,000 U.S. opt-outs, and possible additional charges that cannot be estimated.

03—Questions

Frequently Asked Questions

Why did reported earnings decline in 1994 if the core business grew?
Reported net earnings fell to $1.84 billion from $1.96 billion because of a $750 million pre-tax special charge in Q4 1994 for pending and future breast implant product liability claims. Pre-tax earnings before this charge rose 8% to $3.31 billion, and net earnings before the charge rose 3% to $2.33 billion. The 1993 results also included a $500 million charge, so the comparison is affected by both years.
How large could the breast implant liability ultimately be?
The settlement caps the aggregate contribution of the Company and its subsidiary MEC at $1.154 billion, paid over roughly 30 years. The company recorded $1.5 billion of liabilities in 1993 against $1 billion of expected insurance proceeds, and then took the additional $750 million charge in 1994. However, about 3,000 U.S. opt-outs and about 2,200 foreign opt-outs may bring claims outside the settlement, and the company says the cost of resolving them cannot be reliably estimated. Further charges are possible, and the timing of a potential trigger for settlement reductions is uncertain, though likely not before late 1995.
What is the biggest patent risk for the company's largest product?
Captopril, sold mainly as CAPOTEN, is the company's largest-selling product, with 1994 sales of $1.5 billion, of which $581 million were in the U.S. Under legislation implementing the GATT treaty, the U.S. patent expiration was pushed to February 1996. The company says the financial effect of this new date is still being evaluated because of open questions about how the GATT legislation will be implemented. In Germany, patent protection for CAPOTEN expired in February 1995.
Is the company's balance sheet strong enough to support its dividend and investments?
Yes, based on the filing. At year-end 1994 the company held $2.4 billion in cash, time deposits and marketable securities. Operating cash flow was $2.3 billion, which funded about $1.5 billion in dividends, $573 million in capital expenditures, and $667 million for acquisitions. The company also has a triple-A credit rating and substantial unused borrowing capacity. However, short-term borrowings rose to $725 million, largely to finance the UPSA acquisition, and working capital fell from prior years.
What drove growth in the pharmaceutical business?
Pharmaceutical sales grew 7% to $6.97 billion, mainly from volume, with price increases adding about 1%. Cardiovascular drugs reached $2.8 billion and grew 8%, helped by Pravachol and Monopril. Anti-cancer sales rose 13% to $1.3 billion, with Taxol performing strongly after its April 1994 U.S. clearance for metastatic breast cancer. CNS drugs grew 17%, led by Stadol NS and Buspar. Anti-infective sales declined 2% to $1.5 billion, as generic competition for Amikin and lower sales of Azactam and Videx offset gains in Cefzil and Zerit. The company also received FDA approval for Serzone in December 1994 and expects to launch Glucophage in 1995.

04—Continue

← View all 10-K filings